BCR/ABL1 was more significantly detected in 24.4% of ALL cases (n=19) (p<0.001), while other molecular abnormalities were detected among the AML group (P=0.001). As for the risk stratification among all the cohorts, 3 groups were identified: favorable [n=71(32.0%)], intermediate [n=86 (38.7%)], and poor [n=65 (29.3%)] with more AML patients in the intermediate and more ALL patients in poor risk groups (P<0.001) (Table 1). This evidence concerns the gene BCR and acute myeloid leukemia.